Changes of bone markers during long-term intravenous calcitriol therapy in maintenance dialysis patients

Mineral and Electrolyte Metabolism

Volumn 22, Issue 4, 1996, Pages 219-223

  Lee, Su Hui ^a   Huang, Tien Shang ^b   Hsieh, Su Jong ^a  

^a SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Bone marker; Intravenous calcitriol; Uremia

Indexed keywords

ALKALINE PHOSPHATASE; BETA 2 MICROGLOBULIN; CALCIFEDIOL; CALCITRIOL; CALCIUM; COLLAGEN TYPE 1; OSTEOCALCIN; PARATHYROID HORMONE; PHOSPHORUS;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPLICATION; DIAGNOSIS; DRUG THERAPY; FEMALE; HEMODIALYSIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; MALE; OSTEOLYSIS; PREVENTION; PRIORITY JOURNAL;

ADULT; ALKALINE PHOSPHATASE; BETA 2-MICROGLOBULIN; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; BONE RESORPTION; CALCITRIOL; CALCIUM; COLLAGEN; COLLAGEN TYPE I; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; OSTEOCALCIN; PARATHYROID HORMONE; PEPTIDE FRAGMENTS; PEPTIDES; PHOSPHORUS; PROCOLLAGEN; RENAL DIALYSIS;

EID: 0029996548     PISSN: 03780392     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Sherrard DJ, Andress DL: Renal osteodystrophy; in Schrier RW, Gottschalk CW (eds): Diseases of the Kidney, ed 4, Boston, Little Brown, 1988, vol 3, pp 3035-3061.
2. Portale AA, Booth BE, Tsai H, Morris RC Jr: Reduced plasma concentration of 1,25-dihydroxyvitamin D in children with moderate renal insufficiency. Kidney Int 1982;21: 627-632,
3. 3 may be responsible for the development of hyperparathyroidism in early chronic renal failure. Proc Eur Dial Transplant Assoc 1985;22: 1124-1128.
4. Chertow BS, Baylink DJ, Wergedal JE, Su MH, Norman AW: Decrease in serum immunoreactive parathyroid hormone in rats and in parathyroid hormone secretion in vitro by 1,25-dihydroxycholecalciferol. J Clin Invest 1975; 56:668-678.
5. Au WYW, Bukowsky A: Inhibition of PTH secretion by vit D metabolites in organ cultures of rat parathyroids. Federal Proc 1976;35: 530-536.
6. Slatopolsky E, Lopez-Hilker S, Delmez J, Dusso A, Brown A, Martin KJ: The parathyroid-calcitriol axis in health and chronic renal failure. Kidney Int 1990;suppl 29: S 41-47.
7. Slatopolsky E, Weerts C, Thielan J, Horst R, Harter H, Martin KJ: Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients. J Clin Invest 1984;4:2136-2143.
8. 3. J Biol Chem 1983;258: 9100-9107.
9. Delmez JA, Tindira C, Grooms P: Parathyroid hormone suppression by intravenous 1,25 dihydroxy-vitamin D. J Clin Invest 1989;83: 1349-1355.
10. Andress DL, Norris KC, Coburn JW, Slatopolsky EA, Sherrard DJ: Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med 1989;321: 274-279.
11. Gallierir M, Brancaccio D, Padovese P: Low-dose intravenous calcitriol treatment of secondary hyperparathyroidism in hemodialysis. Kidney Int 1992;42:1191-1198.
12. Quarles LD, Davidai GA, Schwab SJ: Oral calcitriol and calcium: Efficient therapy for uremic hyperparathyroidism. Kidney Int 1988;34: 840-844.
13. 3. N Engl J Med 1972; 287:891-895.
14. Memmos DE, Eastwood JB, Talner LB, Gower PE, Curtis JR, Phillips ME, Carter GD, Alaghband-Zadeh J, Roberts AP, de Wardener HE: Double-blind trial of oral 1,25-dihydroxy vitamin D versus placebo in asymptomatic hyperparathyroidism in patients receiving maintenance hemodialysis. BMJ 1981;282: 1919-1924.
15. Baker LR, Muir JW, Sharman VL, Greenwood RN, Cattell WR, Goodwin FJ, Marsh FP, Adami S, Hately W: Controlled trial of calcitriol in hemodialysis patients. Clin Nephrol 1986;26:185-191.
16. Healy MD, Malluche HH, Goldstein DA, Singer FR, Massry SG: Effects of long-term therapy with calcitriol in patients with moderate renal failure. Arch Intern Med 1980;140: 1030-1033.
17. Voigts AL, Felsenfeld AJ, Llach F: The effects of calciferol and its metabolites on patients with chronic renal failure. Arch Intern Med 1983;143:1205-1211.
18. Nordal KP, Dahl E: Low dose calcitriol versus placebo in patients with predialysis chronic renal failure. J Clin Endocrinol Metab 1988; 67:929-936.
19. 3 pulse therapy. Nephron 1989;51: 130-131.
20. Trachtman H, Gauthier B: Parenteral calcitriol for treatment of severe renal osteodystrophy in children with chronic renal in sufficiency. J Pediatr 1987;110:966-970.
21. Hamdy NA, Brown CB, Kanis JA: Intravenous calcitriol lowers serum calcium concentrations in uremic patients with severe hyperparathyroidism and hypercalcemia. Nephrol Dial Transplant 1989;4:545-548.
22. Price PA, Baukol SA: 1,25-Dihydroxyvitamin D increase synthesis of vitamin K-dependent bone protein by osteosarcoma cells. Biol Chem 1980;255:11660-11663.
23. Price PA, Parthemore JG, Deftos LJ: New biochemical marker for bone metabolism. J Clin Invest 1980;66:878-883.
24. Demiaux B, Arlot ME, Chapuy MC, Meunier PJ, Delmas PD: Serum osteocalcin is increased in patients with osteomalacia: Correlations with biochemical and histomorphometric findings. J Clin Endocrinol Metab 1992;74: 1146-1151.
25. Hosoda K, Kanzaki S, Eguchi H, Kiyoki M, Yamaji T, Koshihara Y, Shiraki M, Seino Y: Secretion of osteocalcin and its propeptide from human osteoblastic cells: Dissociation of the secretory patterns of osteocalcin and its propeptide. J Bone Miner Res 1993;8: 553-565.
26. Lajeunesse D, Kiebzak GM, Frondoza C, Sacktor B: Regulation of osteocalcin secretion by human primary bone cells and by the human osteosarcoma cell line MG-63. Bone Miner 1991;14:237-250.
27. Risteli J, Elomaa I, Niemi S, Novamo A, Risteli L: Radioimmunoassay for the pyridinoline cross-linked carboxyterminal telopeptide of type I collagen: A new serum marker of bone collagen degradation. Clin Chem 1993;39: 635-641.
28. Eriksen EF, Charles P, Melsen F, Mosekilde L, Risteli L, Risteli J: Serum markers of type I collagen formation and degradation in metabolic bone disease: Correlation to bone histomorphometry. J Bone Miner Res 1993;8(2): 127-132.
29. Melkko J; Niemi S, Risteli L: Radioimmunoassay of the carboxy terminal propeptide of human type I procollagen. Clin Chem 1990; 36:1328-1332.
30. Hamdy NAT, Risteli J, Risteli L, Harris S, Beneton MNC, Brown CB, Kanis JA: Serum type 1 procollagen peptide: A non-invasive index of bone formation in patients on hemodialysis? Nephrol Dial Transplant 1994;9: 511-516.
31. 3 in chronic renal failure (abstract). Bone 1992;13(5):A6.
32. Bommer J: Medical complications of the long-term dialysis patient; in Comeron S, Davison AM, Grunfeld JP, Kerr D, Ritz E (eds): Oxford Textbook of Clinical Nephrology, Oxford, Oxford University Press, 1992; vol 2, pp 1441-1443.
33. 3 administration reduces the serum concentration of 25-hydroxyvitamin D by increasing metabolic clearance rate. J Clin Invest 1986;78:622-628.